Back to results
US 2022/0175901 A1Published application
Delivery of bacteria-derived outer membrane vesicles
AssigneeQuadram Institute Bioscience
InventorsSimon Carding, Regis Stentz
Life of this patent
Estimating the term…
Abstract
Pharmaceutical compositions and preparation including outer membrane vesicles (OMVs) and at least one pharmaceutically acceptable carrier wherein said OMVs are native OMVs produced by the Gram-negative commensal bacteria Bacteroides.
Claims30
1:
- A pharmaceutical preparation including outer membrane vesicles (OMVs) and at least one pharmaceutically acceptable carrier wherein said OMVs are native OMVs produced by the Gram-negative commensal bacteria Bacteroides.
2:
- A pharmaceutical preparation according to claim 1 wherein the pharmaceutically acceptable carrier is buffered saline.
3:
- A pharmaceutical preparation according to claim 1 wherein the pharmaceutical preparation primes, activates and/or boosts immune responses to prevent infection, tissue inflammation, tumor growth and/or other injury.
4:
- A pharmaceutical preparation according to claim 3 wherein said OMVs include and/or deliver biologically active peptides, proteins and/or biologics.
5:
- A pharmaceutical preparation according to claim 4 wherein said pharmaceutical preparation and/or said OMVs are for delivery of said peptides, proteins or biologics to the gastrointestinal (GI) and/or respiratory tract.
6:
- A pharmaceutical preparation according to claim 5 wherein the preparation is to prevent infection, tumour growth, tissue inflammation and/or injury to the gastrointestinal (GI) and/or respiratory tract and other organ systems.
7:
- A pharmaceutical preparation according to claim 1 wherein the native OMVs are delivered to one or more mucosal sites to induce, activate or boost an immune response.
8:
- A pharmaceutical preparation according to claim 1 wherein the pharmaceutical preparation includes at least one pharmaceutically active component or one further pharmaceutically active component to the OMVs.
9:
- A pharmaceutical preparation according to claim 8 wherein the at least one pharmaceutically active component includes a vaccine agent such as antigens and/or pathogen components.
10:
- A pharmaceutical preparation according to claim 9 wherein the OMVs is an adjuvant to reduce the number of doses and/or amount of vaccine agent or component required to elicit a protective immune response.
11:
- A pharmaceutical preparation according to claim 1 wherein the outer membrane vesicle (OMV) composition is for use as an adjuvant which is delivered before, at substantially the same time or after a vaccine or one or more vaccine agents.
12-13. (canceled)
14:
- A pharmaceutical preparation according to 4 wherein the peptide or protein is within or on the outer membrane of OMVs.
15:
- A pharmaceutical preparation according to any preceding claim wherein the species of Bacteroides producing the OMVs includes B. acidifaciens, B. caccae, B. coprocola, B. coprosuis, B. eggerthii, B. finegoldii, B. fragilis, B. helcogenes, B. intestinalis, B. massiliensis, B. nordii, B. ovatus, B. stercoris, B. thetaiotaomicron, B. vulgatus, B. plebeius, B. uniformis, B. salyersai, B. pyogenes, B. goldsteinii, B. dorei and B. johnsonii and B. xylanisolvens.
(canceled)
17:
- A pharmaceutical preparation according to claim 15 wherein a mannan-inducible expression system is used in any Bacteroides.
18:
- A pharmaceutical preparation according to claim 1 wherein the OMVs are provided by B. thetaiotaomicron (Bt) (VPI-5482), and strains thereof, including GH193, GH359 or GH364.
19:
- A pharmaceutical preparation according to claim 8 wherein the pharmaceutical preparation includes Salmonella typhimurium-derived vaccine antigens.
(canceled)
21:
- A pharmaceutical preparation according to claim 8 wherein the pharmaceutical preparation includes influenza A virus (IAV) derived vaccine antigens.
22-23. (canceled)
24:
- A pharmaceutical preparation according to claim 8 wherein immunisation is with OMVs containing the core stalk region of the IAV H5 hemagglutinin from an H5N1 strain, inducing heterotypic protection.
(canceled)
26:
- A pharmaceutical preparation according to claim 1 wherein said composition includes a heterologous peptide, protein or biologic.
(canceled)
28:
- A pharmaceutical preparation according to claim 1 wherein the composition is for use in a method for the treatment of typhoid.
29:
- A pharmaceutical preparation according to claim 1 wherein the composition is for use in a method for the treatment of colitis.
30:
- A pharmaceutical preparation according to claim 1 wherein the native OMVs are delivered intranasally.
31:
- A pharmaceutical preparation according to claim 1 wherein administration of said OMVs provides anti-tumour properties.
32-36. (canceled)
Dependencies are inferred from the claim text.